Huminsulin Basal (Nph) Für Pen Lilly Deutschland (Insulin Human)

Huminsulin Basal (Nph) is indicated for the basal insulin needs of adults and children with diabetes. It is used as part of a comprehensive diabetes management plan that may include diet, exercise, and other glucose‑lowering agents.

• Long‑acting insulin therapy for type 1 diabetes mellitus.
• Basal insulin support in type 2 diabetes mellitus.
• Adjunct to rapid‑acting insulin for mixed‑dose regimens.
• Used when a steady insulin level is required over 12‑24 hours.
• May be prescribed for patients transitioning from multiple daily injections to a pen device.

• Huminsulin Basal (Nph) contains insulin human that binds to insulin receptors on muscle, adipose, and hepatic cells. This binding activates the receptor’s tyrosine kinase activity, promoting translocation of GLUT‑4 transporters to the cell surface, which increases glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby reducing endogenous glucose production and lowering circulating blood glucose levels.

Adverse reactions can vary in frequency and severity. Patients should be aware of both common and serious potential effects.

Common

• Hypoglycemia (low blood glucose)
• Injection site redness or swelling
• Lipodystrophy at the injection site
• Weight gain
• Mild headache

Serious

• Severe hypoglycemia with loss of consciousness
• Allergic reactions such as rash, urticaria, or anaphylaxis
• Edema or fluid retention
• Persistent hyperglycemia indicating insulin resistance

Huminsulin Basal (Nph) requires careful monitoring and consideration of individual health factors before use.

• Verify blood glucose levels regularly to adjust dose as needed.
• Use caution in patients with renal or hepatic impairment.
• Assess for signs of hypoglycemia, especially in the elderly.
• Avoid use during pregnancy unless benefits outweigh risks.
• Store the pen according to manufacturer instructions to maintain potency.
• Do not share pens or needles to prevent cross‑contamination.

Huminsulin Basal (Nph) may interact with other medications, altering its efficacy or safety profile.

Avoid

• Concurrent use of other insulin products without dose adjustment.
• High‑dose beta‑blockers that may mask hypoglycemia symptoms.
• Alcohol excess, which can potentiate hypoglycemia.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which may raise blood glucose levels.
• Thyroid hormones, as they can affect insulin sensitivity.